WJPR Citation New

  All Since 2019
 Citation  7475  4312
 h-index  28  21
 i10-index  197  83

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
Best Paper Award :
Dr. Dhrubo Jyoti Sen
Download Article: Click Here

Search

Track Your Article

Abstract

A REVIEW ON: NOVEL DRUG DELIVERY TECHNOLOGY OF RITUXIMAB

Ni Made Dwi Indrayuni*, Erfan Tri E., Baharudin Irfan, Sari Kusuma Hati and Siti Saharah Abdullah

Abstract

Rituximab can be used for the treatment of severe rheumatoid arthritis, follicular lymphoma phase III-IV, follicular non-hodgkins lymphoma, chronic lymphocytic leukimia therapy, advance therapy of granulomatosis polyangiitis and microscopic polyitis. Rituximab is a two compartment with an average half-life of 87 ± 18 hours and a volume distribution of 1.3L. Administration of rituximab at a dose of 375 mg / m2 in 4 consecutive weeks can increase serum drug concentration in each administration by infusion. This review article focuses on biosimilar technology of rituximab was carried out by increasing the teraupetic mechanism and the response to the potential effects of binding B-mAB in NHL disease. The development of biosimilar rituximab approved by the FDA, namely ofatumab (anti CD20) and Obinutuzumab (mAb from rituximab with a different glucose group).

Keywords: Rituximab, Biosimilar, NHL disease.


[Full Text Article]  [Download Certificate]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More